NICE changes tack on ‘game changer’ rare cancer therapy PoteligeoNICE has reversed an earlier decision not to recommend NHS use of Kyowa Kirin’s Poteligeo for two rare Share XNICE changes tack on ‘game changer’ rare cancer therapy Poteligeohttps://pharmaphorum.com/news/nice-changes-tack-on-game-changer-rare-cancer-therapy-poteligeo/
Boost for AZ as Ultomiris gets CHMP nod for expanded labelFresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion Share XBoost for AZ as Ultomiris gets CHMP nod for expanded labelhttps://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/
Scotland backs rare blood cancer drug Poteligeo rejected by NICEA north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s Share XScotland backs rare blood cancer drug Poteligeo rejected by NICEhttps://pharmaphorum.com/news/scotland-backs-rare-blood-cancer-drug-poteligeo-rejected-by-nice/
Amgen pays Kyowa $400m upfront for OX40 eczema drugAmgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim Share XAmgen pays Kyowa $400m upfront for OX40 eczema drughttps://pharmaphorum.com/news/amgen-pays-kyowa-400m-upfront-for-ox40-eczema-drug/
Kyowa Kirin backs €125m life science fund closed by Fountain HealthcareIreland-based Fountain Healthcare Partners has raised another €125 million ($131 million) for its third life sciences fund – Share XKyowa Kirin backs €125m life science fund closed by Fountain Healthcarehttps://pharmaphorum.com/news/kyowa-kirin-backs-e125m-life-science-fund-closed-by-fountain-healthcare/
GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rivalGlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas. Marketed Share XGSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rivalhttps://pharmaphorum.com/news/gsk-kidney-disease-anaemia-drug-approved-in-japan-taking-on-astellas-rival/
FDA approves Kyowa Kirin’s new Parkinson’s drug NourianzThe FDA has approved a new drug for Parkinson’s disease, giving the nod to Kyowa Kirin’s Nourianz (istadefylline) Share XFDA approves Kyowa Kirin’s new Parkinson’s drug Nourianzhttps://pharmaphorum.com/news/fda-approves-kyowa-kirins-new-parkinsons-drug-nourianz/
Could Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?Kyowa Kirin has bought back rights outside of cancer to tivozanib, amending an agreement dating back to 2006 Share XCould Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?https://pharmaphorum.com/news/could-kyowa-kirin-be-eyeing-ophthalmology-use-for-cancer-drug-tivozanib/
EU approves Kyowa Kirin’s drug for rare lymphomaThe European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is Share XEU approves Kyowa Kirin’s drug for rare lymphomahttps://pharmaphorum.com/news/eu-approves-kyowa-kirins-drug-for-rare-lymphoma/
